提醒

提醒专业图表

Grifols S.A. (GRFS)

NasdaqGS: GRFS · 实时价格 · USD

7.78

-0.15 (-1.89%)

收盘价： Aug 14, 2026, 3:59 PM

7.78

+0.00%

盘后: 4:10 PM

-1.89% (1D)

买价	6.78
市值	5.29B
营收（TTM）	7.42B
净利润（TTM）	452M
贝塔值	1.19
每股收益（TTM）	0.75
市盈率（TTM）	10.37
预期市盈率	5.46
市净率（TTM）	1.66
市销率（TTM）	0.71
Earnings Date	Feb 25, 2027

卖价	8.93
成交量	256,699
20日均量	677,462
开盘价	7.92
前收盘价	7.93
日内区间	7.76 - 7.96
52周区间	6.96 - 10.65
分析师	Buy
目标价	10.87 (39.72%)
分红	$0.28 (3.55%)
除息日	2026年7月2日

关于 GRFS

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurol...

[阅读更多]

行业 Drug Manufacturers - General

板块 Healthcare

上市日期 Jun 2, 2011

员工人数 25,258

交易所 NasdaqGS

股票代码 GRFS

官网 https://www.grifols.com

公司完整简介

财务表现

2025年，Grifols S.A.的营收为7.52B，较上一年的7.21B增长4.33%。净利润为402M，增长156.05%。

财务报表

分析师预测

根据2位分析师的评级，GRFS的平均评级为“Buy”。12个月目标价为10.87，较最新价格上涨空间39.72%。

股票预测

财报意外

Grifols S.A. 已于 Jul 28, 2025 发布季度财报：

营收为 $1.87B 低于预期 $0, ， 4.93% 同比增长.

每股收益为 0.22 低于预期 -0.06, ， -24.14% 同比下滑.

下次财报发布时间

Grifols S.A. 计划于以下时间发布财报 Feb 25, 2027, 盘中。
分析师预计营收为 ... 升级

新闻

1周前 · MT Newswires

European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading

European equities traded in the US as American depositary receipts were edging higher late Wednesday

2周前 · Motley Fool

Grifols (GRFS) Q2 2026 Earnings Call Transcript

CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.

2周前 · GuruFocus.com

Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ...

Grifols SA (GRFS) reports robust revenue growth and strategic progress, despite facing temporary challenges in key markets.

2周前 · MarketBeat

Grifols Q2 Earnings Call Highlights

Grifols (NASDAQ:GRFS) said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, i...

2周前 · Simply Wall St.

Grifols (BME:GRF) Starts Phase 3 Trials As Undervalued Narrative Faces A Fresh Test

Grifols (BME:GRF) has started dosing patients in two Phase 3 trials for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY, aiming to expand their U.S. labels and potentially broaden future treatment...

第 1 页，共 2 页